New drugs for addiction: focus on attenuating core behavioural components of heroin, cocaine and alcohol addiction

新药成瘾：专注于减轻海洛因、可卡因和酒精成瘾的核心行为成分

• 批准号: G1000018/1
• 负责人: David Nutt
• 金额: $ 205.81万
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2011
• 资助国家: 英国
• 起止时间: 2011 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G1000018%2F1
• 关键词: New; drugs; addiction; focus; attenuating

Addiction to drugs such as heroin, cocaine and alcohol are a major problem in our society and globally. Is it possible to understand the processes that lead to addiction and to develop drugs that can be used for treatment? These are the two major questions that motivate the ICCAM addictions research cluster and this application. The ICCAM cluster brings together clinical and preclinical researchers from Imperial College London, Cambridge and Manchester Universities to address the problem of drug development for addiction. We seek to identify rational potential targets for drug development based upon our understanding of the pharmacology and brain processes engaged in addiction, rather than a random ?shotgun? approach. As a society, many think of addiction to drugs such as heroin, cocaine and alcohol as individual conditions with underlying social causes. This may not be the case with the established clinical condition, and this point of view may have impeded rational drug development for these disorders. The ICCAM cluster has identified multiple potential therapeutic drugs that may be of use in the treatment of addiction and now seeks to develop a ?platform? to rapidly assess their efficacy in humans. The word ?platform? means that we will adopt a common research approach based at each of our three sites to study the effects of particular drugs in human participants on processes that are relevant to addiction. We will use state of the art brain imaging techniques to study the effect of drugs on brain activity while a person responds to rewards, for example. These will be combined with neuropsychological assessment and monitoring of clinical outcomes to develop our research capacity.

海洛因、可卡因和酒精等毒品成瘾是我们社会和全球的一个主要问题。是否有可能了解导致成瘾的过程并开发可用于治疗的药物？这是两个主要的问题，激励ICCAM成瘾研究集群和这个应用程序。ICCAM集群汇集了来自帝国理工学院伦敦、剑桥和曼彻斯特大学的临床和临床前研究人员，以解决成瘾药物开发的问题。我们寻求根据我们对药理学和参与成瘾的大脑过程的理解来确定药物开发的合理潜在目标，而不是随机的？猎枪？approach.作为一个社会，许多人认为海洛因、可卡因和酒精等毒品成瘾是具有潜在社会原因的个人状况。这可能不是确定的临床条件的情况下，这种观点可能会阻碍这些疾病的合理药物开发。ICCAM集群已经确定了多种可能用于治疗成瘾的潜在治疗药物，现在正在寻求开发一种？站台？来快速评估它们在人体中的功效。那个词？站台？这意味着我们将在我们的三个研究中心采用一种共同的研究方法，研究特定药物对人类参与者与成瘾相关的过程的影响。我们将使用最先进的大脑成像技术来研究药物对大脑活动的影响，而一个人对奖励的反应，例如。这些将结合神经心理学评估和临床结果监测，以发展我们的研究能力。